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Summarv Classification of lImphoid malignancy has changed markedly in recent -ears and advances have
been made in therapy. This study investigated the x-anrations in treatment and surviv-al of 1622 patients in a
population-based registrv. A total of 1009 cases of malignant lymphoma (ML) were classified according to the
Kiel classification. Pathology review resulted in major diagnostic changes for 240o of cases. Of the ML cases.
3900 had not had full staging procedures. Younger patients were more likely to have been treated With
multiagent chemotherapy regimens. as were patients with B symptoms. Median survival for ML patients was
12 months for high-grade patients and more than 60 months for low-grade patients. Significant factors
affecting the surVival of ML patients were performance status. whether treatment had followed a recognised
protocol. whether treatment had been carred out at a specialist oncology centre (SOC). grade of disease.
stage. gender and age. The same factors had a significant effect on survial of the leukaemia patients. except
for treatment at an SOC. which had a significant favourable effect on survxival of acute lImphoblastic
leukaemia (ALL) patients only. Median surVival for patients with chronic lymphocytic leukaemia was 43
months and 7 months for ALL patients.
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There are over 450 new cases of non-Hodgkin's ly-mphoma
and lymphoid leukaemia in the North West Region of Eng-
land per year. in a population of 5.3 million.
The diagnosis and classification of these haematological
malignancies has changed markedly over recent years (Ers-
boll et al.. 1985: Wang. 1986: Mead. 1987). Histological
diagnosis is frequently difficult and classification may show
wide variation when opinions of individual pathologists are
compared with those of a lymphoma panel (Bird et al.. 1984:
Dick et al.. 1987a). Recent advances include the development
of therapeutic regimens tailored to the cell type. stage of
disease and presence of prognostic factors (Simon et al..
1988: O'Reilly and Connors. 1992a). It has been suggested
that entrx into clinical trials and treatment at specialist
centres may confer a therapeutic and survival advantage in
patients with some forms of malignanc) (Stiller. 1989. 1992:
Youngson. 1984). One report suggested that the uneven dist-
ribution of experts in cancer care may lead to inadequate
assessment and management (Mclllmurray. 1987). Earlier
work in the North Western Region has shown a wride varia-
tion in diagnostic cnrtenra and management procedures with
inconsistent referral and survival patterns (Youngson, 1984).
The aim of this study was to investigate the patterns of
referral, treatment and survival in a group of patients with
lymphoid malignancy ascertained from a specialist pop-
ulation-based registry with high levels of ascertainment and
diagnostic accuracy.
Materials and methods
A specialist population-based registry for lymphoid leu-
kaemia and non-Hodgkin's lymphoma was established for
the North West Region in 1982. All cases of non-Hodgkin's
lymphoma. the adult T-cell lymphomas (mycosis fungoides.
Sezary syndrome). Waldenstrom's macroglobulinaemia. acute
lvmphoblastic leukaemia (ALL). chronic lymphocytic leu-
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kaemia (CLL). prolymphocytic leukaemia (PLL) and hairy-
cell leukaemia (HCL) were included. Cases were classified
according to the Kiel classification (Gerard-Marchant et al..
1974) and were grouped into low-grade. high-grade and
unclassifiable for analysis. Cases in this studv were classified
as CLL. rather than malignant lymphoma (ML) lymphocytic
if the circulating lymphocyte count was greater than
10 000 cells mm-3. Cases referred to subsequently as CLL
also include the variants PLL and HCL. The International
Classification of Diseases for Oncology (ICDO). WHO
(1976) was used for coding.
Cases registered were aged 15 and over at diagnosis
and resident within the North Western Regional Health
Authority (NWRHA) boundary. Cases were ascertained
from the North West Regional Cancer Registrv (NWRCR).
histopathologists and haematologists throughout the region
and from clinicians writh a particular responsibility for the
management of this group of patients. The diagnoses of all
cases were histologically confirmed and procedures estab-
lished for a central review of diagnostic material. Slides were
reviewed and additional immunostains were performed to
establish lineage and clonality when indicated. The diagnosis
on which the management was based was used in the
analyses of treatment. irrespective of whether the class-
ification changed subsequently.
Cases diagnosed between 1 January 1983 and 31 December
1986 and registered by 1 January 1989 were entered into the
follow-up study. Demographic data and all information
relating to the diagnosis and management were obtained
from hospital records. Copies of death certificates wvere
obtained from the Office of Population Censuses and Surveys
via the NWRCR and the information was validated and
enhanced with information from the hospital records.
The Ann Arbor staging classification was used for patients
with ML (Carbone et al.. 1971). Investigations considered
necessary for clinical staging were chest X-ray. computed
tomographic scanning of the chest and abdomen. or
abdominal lymphography. full blood profile and liver func-
tion tests. If stage was not stated in the case notes. clinical
stage was reconstructed from the results of investigations and
assessment. When cases had not been fully investigated or
when the results of investigations could not be tracedManagemn and survia oflymnph imignancy in Enrend
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patients were allocated a surrogate stage on the available
data. Three levels of surrogate stage were used for these
patients: localised disease. disease limited to one side of the
diaphragm and widespread disease. These were labelled
stages 5. 6 and 7 respectively. The presence of B symptoms
was also recorded and defined as the presence of night
sweats, unexplained fever or weight loss (> 10% of normal
body weight) in the 3 months before diagnosis.
The performance status (PS) of the patient was coded by
the recorded Karnofsky performance status (KP), the Eastern
Cooperative Oncology Group (ECOG) equivalent, or a re-
construction of performance status from information avail-
able in the case notes. Performance status was stratified into
three groups. KP.,90%, ECOGO (PSI), KP 70<90%/
ECOG 1 (PS2) and KP < 70% /ECOG 2 (PS3).
Certain protocols were accepted as appropriate manage-
ment for this group of patients. Details of treatment given
were recorded. whether the treatment given complied with
these protocols and whether patients had been entered into
clinical trials. Stated reasons for other treatment regimens or
no treatment were recorded. Patients were regarded as having
no treatment when there was no apparent intention to treat
as opposed to a stated 'watch and wait' policy. Analysis was
on an intention to treat basis. Hospitals carrying out the
treatment were designated either as a regional specialist
oncology centre (SOC). which included jointly run clinics and
jointly organised care at other hospitals, or 'other hospitals'.
Statistical methods
Independent variables considered in the analysis were age.
gender. social class. treatment at a SOC. PS, grade of disease.
site of disease, protocol. stage and the presence of B symp-
toms. The effect of each variable on the decision to treat was
assessed individually by performing a univariate analysis.
Categorical variables were analysed using the chi-square test
and age by one way analysis of variance.
Survival curves were computed by an actuarial method
(Berkson and Gage. 1950) with an interval of 1 month, using
the computer package BMDP1L (BMDP, 1992). The survival
curves for the subgroups of each independent variable were
compared using the log-rank test (Peto and Peto, 1972).
Simultaneous effects of the variables on survival were ex-
plored using Cox's multivariate model (Cox, 1972). The com-
puter package BMDP2V (BMDP, 1992) was used to fit Cox's
proportional hazards model to the data. A forward stepwise
procedure was used to select significant variables, taking a
5% level of significance as the critical value. First-order
interaction effects between variables were incorporated into
this process. Tests of significance of the variables or the
variables with interaction terms have been presented. Plots of
the log cumulative hazard function against time for each
stratum of the prognostic variables used in the analyses did
not reveal any violation of the proportional hazards assump-
tion.
Survival was measured from the date of diagnosis, with the
event of interest being death from any cause. Patients who
died before the diagnosis was pathologically confirmed were
taken to have a survival time of 0 months. Separate analysis
of death from the disease of interest have not been presented
as the number of unrelated deaths was small.
An exploration of the effects of factors on the survival of
leukaemia patients was initially undertaken separately for the
patients with ALL and for the CLL patients. Cox's mul-
tivariate analysis used data for all leukaemia patients in
order to identify significant prognostic factors common to
both types of leukaemia as well as to detect variables whose
effects on survival differ between ALL and CLL patients.
Results
There were 1663 patients entered into the study-. The median
follow-up was 33 months (range 1 -65 months). Table I
shows the reason for excluding cases.
Malignant lvmphoma
The 1009 cases classified as ML had an age range of 17-95
years (median 66). The male to female ratio was 1.2:1. The
majority (59%) presented with nodal disease and 31% with
disease at an extranodal site: 10% of cases were diagnosed
on bone marrow examination only.
A total of 391 (39%) of ML cases had not been fully
evaluated for stage using recommended procedures. There
was sufficient evidence of bone marrow or organ involvement
in 140 of these cases to code them as stage 4; 251 cases were
designated as stages 5. 6 or 7: 60% of these patients were
aged 70 or over but onlyr 15% were recorded as PS3. Table II
shows the management of this patient group.
Of the 103 patients diagnosed on examination of the bone
marrow. 56 had not been fully investigated and 58 were aged
70 or over. Nine patients were coded to PS3. the same
proportion as for all patients.
A total of 149 ML patients were recorded as having
received no therapy. Patients who did not receive treatment
were significantly older than patients who were given
therapy, with 66% being aged 70 or over compared to 32%
of treated patients. Untreated patients were more likely to
have presented as PS3 (39%) and only 28% were recorded as
PSI compared with 10% and 66% of treated patients.
Eighty-three per cent had not been fully investigated com-
pared with 31% for treated cases. Only 18% of this patient
group was seen at an SOC.
Only 159 patients (119 ML, 16 ALL, 24 CLL) were
recorded as having been entered into randomised clinical
trials. Of the ML cases, 111 were managed at an SOC
representing only 18% of ML cases so managed. Numbers of
cases therefore were too small to allow a meaningful inter-
pretation of the effects of clinical trial entry in a multivariate
analysis. Both low- and high-grade ML patients. PSI or PS2
and aged less than 70, fared better in clinical trials but the
difference did not achieve statistical significance for low-
grade patients (P = 0.14). but was significant for high-grade
patients (P = 0.04).
Table I Reasons for exclusion of cases
Malignant lymphorna
Not
High-grade Low-grade classifiable
L.ekaemia Total
High-,rade Low-zradep All cases
Original number 557 405 76 76 549 1663
Referral post therapy 16 9 4 4 8 41
Total 541 396 72 72 541 1622
Lost to follow-upc 9 5 - - 15 29
Final total 532 391 72 72 526 1593
'Acute lymphoblastic leukaemia. sChro.'c lymphocytic leukaerma and van.ants. 'Excluded from survival
analyses.
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Table n Treatment of lymphoma patients who had not been fully evaluated for staging
Soc Other hospital
Stage 4 Stages 5-7 Stage 4 Stages 5-7 Total
Treatment n % n % n % n 0 n %
None 3 7.5 26 18.7 53 53.0 68 60.7 150 38.4
Multiagent CT 18 45.0 22 15.8 17 17.0 18 16.1 75 19.2
Single-agent CT 8 20.0 14 10.1 28 28.0 25 22.3 75 19.2
Radical XRT - - 24 17.3 - - - - 24 6.1
Palliative XRT 11 27.5 53 38.1 - - - - 64 16.4
Notknown - - - - 2 2.0 1 0.9 3 0.8
Total 40 100.0 139 100.0 100 100.0 112 100.0 391 100.0
SOC. specialist oncology centre; CT. chemotherapy; XRT. radiotherapy.
Table III Treatment oflymphoma patients according to hospital oftreatment and
grade of disease
ML low grade ML high grade
SOC Other hospital SOC Other hospital
Treatment n % n % n % n %
None 11 3.4 24 17.4 8 3.0 41 50.6
Multiagent CT 85 26.2 34 24.6 99 37.5 20 24.7
Single-agent CT 70 21.6 43 31.2 9 3.4 12 14.8
Radical XRT 41 12.7 1 0.7 34 12.9 - -
Palliative XRT 46 14.2 2 1.4 30 11.4 1 1.2
CT + XRT 48 14.8 2 1.4 80 30.3 - -
Watch and wait 23 7.1 21 15.2 4 1.5 1 1.2
Not known - - 11 8.0 - - 6 7.4
Total 324 100.0 138 100.0 264 100.0 81 100.0
SOC. specialist oncology centre; CT. chemotherapy; XRT. radiotherapy.
Histology review
The effect of histology review on diagnosis was investigated
for 498 ML cases diagnosed during 1985 and 1986. In 264
(53%) the diagnosis remained unchanged. Of the 234 (47%)
cases where the diagnosis changed 114 were reclassified,
according to the Kiel classification, within the same grade of
disease. For the remaining 120 (51%) cases the change was
clinically a major one. Nine of these 234 cases (4%) were
originally diagnosed as malignancies other than lymphoma
and 15 cases (6%) as Hodgkin's disease. Fifty cases (21%)
were classified specifically from an initial diagnosis of 'Iym-
phoma' and 46 (20%) changed grade of disease. Therefore
the reviewed diagnosis would have affected the clinical
decision with regard to therapy in 24% of the 498 cases.
As patients referred to the SOC were more likely to have
had diagnostic material reviewed in the first 2 years of the
study, before the establishment of central review, survival
correlated with whether histology had been reviewed. Subse-
quent survival analysis was restricted to patients where the
diagnostic material had been reviewed. A total of 842 (83%)
of the 1009 ML patients remained with diagnostic review,
and of these, the histology of 45 could not be classified into
high- or low-grade disease so that analyses including grade of
disease are based on 797 cases.
Treatment
Table III shows the numbers of high-grade and low-grade
patients treated by different policies for the SOC and other
hospitals. Radiotherapy was only a treatment option at the
regional radiotherapy centre. The analysis of treatment inten-
tion at other hospitals therefore addressed the question of
factors affecting the decision to give chemotherapy. The
treatment groups considered were a 'watch and wait' policy,
single-agent chemotherapy and multiagent chemotherapy.
The same treatment groups analysed for patients treated at
the SOC plus radiotherapy and radiotherapy combined with
multiagent chemotherapy.
Low-grade ML
Analysis of factors affecting the decision to give
chemotherapy at 'other hospitals' was based on 98 patients.
Thirty-four patients were treated with multiagent
chemotherapy. 43 with single agent therapy and 21 by a
'watch and wait' policy.
The distribution of age differed significantly (P = 0.009)
between the three treatment groups. Patients given multi-
agent chemotherapy were younger (mean age 63) than
patients given single agent therapy (mean age 71). Patients
were significantly less likely to be given multiagent chemo-
therapy if the presenting site of disease was extra-nodal or if
they did not have B symptoms at the time of diagnosis.
The same factors varied significantly between the patient
groups when the treatment of 267 patients managed at the
SOC was considered. Patients presenting with extra-nodal
disease were significantly more likely to be managed with
regimens including multiagent chemotherapy or radical
radiotherapy. Patients with B symptoms were significantly
more likely to be managed with multiagent chemotherapy
protocols. Age was also a significant factor. The mean age of
patients managed with multiagent chemotherapy protocols
was 56 compared to 64 for those treated with radical
radiotherapy only.
High-grade ML
Only 32 of the patients with high-grade disease managed at
'other hospitals' had chemotherapy recorded (Table III).
Numbers therefore were too small to permit a meaningful
analysis. A total of 213 patients with high-grade disease wereMa_lagmm ma swvo d1mp_oW ..5p.AryiEr4wd g JHA~~~~~~~~~~~~~~M Youngson etat
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managed at the SOC with multiagent chemotherapy or
radical radiotherapy regimens. The significant factors were
presenting site of disease and the presence of B symptoms.
Age was of borderline significance (P = 0.05). Patients
treated with radical radiotherapy only were more likely to
present with extra-nodal disease and were older, with a mean
age of 61 compared with 54 for patients given protocols
including multiagent chemotherapy. No patient with B symp-
toms was given radiotherapy alone.
Leukaemia
The age range for CLL patients was 32-96 years with a
median age of 71 years. The male to female ratio was 1.3:1.
The median age of ALL patients was 48 (range 15-99), with
a male to female ratio of 1.4:1.
CLL treatment Analysis was based on data from 541
patients. Treatment details were not traced for 42 (8%)
patients and 72 (13%) patients were not treated. A total of
427 patients had treatment recorded and of these 19 (4%)
were given multiagent chemotherapy regimens, 139 (33%)
single agent chemotherapy and 264 (62%) were treated
according to a 'watch and wait policy. Five patients received
radiotherapy only.
A total of 372 patients managed at 'other hospitals' were
analysed with respect to factors affecting the decision to give
or defer chemotherapy. Males were significantly more likely
(63%) than females (37%) to be given chemotherapy. There
was no effect of age, PS or social class.
Of the 60 patients managed at the SOC, five patients
received no therapy, two patients were managed with
radiotherapy, 29 (48%) received chemotherapy and 24 (40%)
were managed with a 'watch and wait' policy. There
appeared to be no effect of age, gender, PS or social class on
the decision to give chemotherapy. Proportionally more
patients were given chemotherapy than at 'other hospitals'
(P = 0.003).
ALL treatment
Seventy-two patients with ALL were analysed. Fifty-five
(76%) patients were treated with multiagent chemotherapy
regimens and 17 patients were untreated or received palliative
therapy only. Four patients received bone marrow transplan-
tation in first remission. Forty-one patients were managed at
Table IV Lymphoma patients. Vanrables examined for a possible effect on survival
Nunber Nunber
of of
Variable Level patients deaths
Age
Gender
Social class
SOC
PS
B symptoms
Stage
Grade
Presenting site
Presenting site
Protocol
SOC and grade
SOC and protocol
Protocol and grade
<40
40-49
50-59
60-69
70-79
) 80
Male
Female
I and 2
3
4
5
No
Yes
)90o (KP1)
70-89% (KP2)
<70% (KP3)
Absent
Present
2
3
4
5
6
7
Low grade
High grade
Node
Maltoma
Bone marrow
Other
Nodal
Extra-nodal
No
Yes
No, low grade
No, high grade
Yes, low
Yes, high
No, no protocol
No. protocol
Yes, no protocol
Yes, protocol
No, low grade
No, high grade
Yes, low
Yes, high
SOC, specialist oncology centre.
73 26
85
160
239
214
71
455
387
170
351
121
57
211
631
410
165
76
565
250
82
106
103
352
52
82
53
455
342
499
124
74
145
499
343
292
538
118
72
337
270
107
94
185
444
136
130
311
208
Median
survival
(months)
>60
>60
>60
36
13
6
27
42
42
35
29
26
7
46
>60
16
4
46
15
>60
>60
49
29
50
11
4
>60
12
35
35
24
34
35
33
10
>60
27
l
>60
28
l
35
28
>60
28
5
>60
35
24
61
111
145
53
241
179
75
173
67
32
145
275
148
102
60
244
153
12
45
45
186
22
56
44
179
209
245
61
39
75
245
175
195
214
62
66
117
143
94
42
101
172
72
101
100
104
Percentage
survival
(2 <sears}
69
73
66
59
37
26
51
58
60
55
51
52
33
61
68
42
27
61
43
88
63
60
51
63
38
19
66
42
55
56
49
52
55
53
38
64
50
9
71
51
13
59
52
66
52
27
73
52
P-value
(log-rank)
0.9 x 10-19
0.042
0.19
0.7 x 10`:
<0.3 x 10-21
0.6 x 10-6
<0.4 x 10-1
0.6 x 10-12
0.87
0.77
0.2 x 10- 19
<3.0x 10-20
<3.0 x 10-:
<3.0 x 10`-an SOC and all but two received treatment as opposed to 13
of the 31 patients managed locally (P<0.001). Patients over
50 were less likely to be given chemotherapy (P<0.001).
Eight of the 15 untreated patients were over 80 years of age.
Patients managed at the SOC were significantly younger than
those managed at 'other hospitals', 71% were aged less than
50 compared with 31% of patients managed at other hos-
pitals.
ML survival
A total of 420 patients had died. Seventy-eight deaths were
due to causes other than lymphoma. Seven patients died
from intercurrent causes with no disease present, 40 patients
died from intercurrent causes with active disease, 16 patients
died from second malignancy and for 15 patients death was
associated with the toxicity of therapy.
The 2 year survival, for the 842 patients, was 54% with a
median survival time of 34 months. Survival curves for the
prognostic factors are summarised in Table IV.
Patients treated at an SOC had a much improved prog-
nosis compared to patients treated at 'other hospitals'.
Patients treated according to a standard protocol had a
better prognosis. The survival curves for each combination of
the variables SOC, protocol and grade are shown in Figures
I and 2.
As the survival curves by age revealed that there was little
difference in the survival patterns for patients under 70 years,
age was handled in the Cox analysis as a three category
variable (<70, 70-79, >80). Stages 2, 3 and 5 had very
similar survival patterns and hence stage was regrouped into
five categories. As there was a very clear trend in survival,
stage was handled as a continuous vanrable. Table V lists the
most significant effect at each step of the Cox analysis. PS
was the most significant variable related to survival. Several
interaction effects were incorporated into the Cox model.
These suggested that PSI and PS2 patients had a better
survival if treated by a recognised protocol but that protocol
had little influence on the survival of patients with a low PS;
the importance of protocol was most marked for patients
treated at hospitals other than the SOC; the improved sur-
vival for patients treated at the SOC was particularly marked
for high-grade patients. Stage, gender and age were also
MIbagetnd andsual d ly maignan mEngland
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independently related to survival with survival being better
for stage 1 patients and for females. Patients aged under 70
years fared better than patients aged 70-79 and those aged
80 and over.
Leukaemia survival
Thirty-two patients died from malignancy other than
leukaemia and no patient died of a cause other than malig-
nancy. Survival curves for the prognostic factors are sum-
marised in Tables VI and VII.
CLL The overall median survival was 43 months, with a 2
year probability of survival of 61%. Social class 1 and 2
patients appeared to have a survival advantage compared to
social class 3 to 5 patients (P = 0.018). The survival curves
for the combination of the variables SOC and protocol are
shown in Figure 3. There were only ten patients who were
treated at the SOC without a recognised protocol.
ALL The survival experience of 72 patients was analysed.
The overall 2 year survival was 34% with a median survival
1.0
0.9 Log-rank P< 0.01
0.8
0.7
cJ 0.6
._
0.
0
0.4
C0)
0.3
0.2 Group 3
(n= 15)
0.1
1.0
0.0 -_
0 Log-rank P< 0.01
0.9 -
Group 1
(n= 193)
Group 2
(n= 77)
Group 4
(n= 53)
6 12 18 24 30 36 42 48 54 60
Time (months)
0.8
-Group 1
------- (n 238)
0 0.6 Group 3
__ _ _(n-73)
0.5 -__ Group 2
=97)
. 0.4
cn
0.3
Group 4
0.2 (n=39)
0.1
0.0
0 6 12 18 24 30 36 42 48 54 60
Time (months)
Fiue 1 Survival of low-grade lymphoma by specialist oncology
centre (SOC) and protocol. Group 1, SOC and protocol; group 2,
SOC and no protocol; group 3. protocol not SOC; group 4, not
SOC and no protocol.
Figure 2 Survival of high-grade lymphoma by specialist
oncology centre (SOC) and protocol. Group 1. SOC and pro-
tocol; group 2, SOC and no protocol; group 3. protocol not
SOC; group 4. not SOC and no protocol.
Table V Final Cox's model for survival for lymphoma patients
MLE ofregression s.e. ofthe
Variables P-value coefficient estimate
PS 0.9 x 10-, 0.562 0.2659
Protocol and 0.8 x 1-4 ' - 1.3705 0.6073
PS protocola -0.0701 0.1654
SOC and 0.7 x 10-16 - 1.0971 0.6725
protocol SOO 0.5654 0.2945
Grade and 0.6 x 10`10 1.2380 0.4916
SOC grade3 -0.2698 0.2769
Stage 0.00012 0.2717 0.0749
Gender 0.0026 -0.4784 0.1265
Age <70 years 0.0017 - 0.2630 0.2256
70-79 years 0.2904 0.2145
MLE. maximum likelihood estimate: s.e.. standard error: PS.
performance status: SOC. specialist oncology centre. 'Denotes
first-order interaction effect.Maus med aIn swrival dmympai malp-ncY in Eniand
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Table VI Variables examined for possible effect on survival from
lymphocytic leukaemia patients
diagnosis for chronic
Variable
Age in years
Gender
PS
Social class
Protocol
SOC
Protocol and SOC
Level
<60
60-69
70-79
. 80
Male
Female
90%
70-89%
<70%
1 and 2
3
4
5
Yes
No
Yes
No
Yes Yes
Yes No
No No
Number of
patients
80
136
197
113
Number of
deaths
24
50
98
78
MUedian
months
57
53
42
13
295 148 40
231 102 48
223
85
63
85
180
86
50
61
53
49
37
100
50
29
2 sear
survival
82
74
62
37
61
65
>60 81
18 44
5 29
50
26
27
25
72
51
55
51
343 95 54 69
158 133 18 48
60 28 57 68
466 222 42 60
50
293
148
22
111
89
57
53
18
72
69
47
PS. performance status; SOC, specialist oncology centre.
Table VII Vanrables examined for possible effect on survival from diagnosis for acute
lymphoblastic leukaemia patients
2 sear
Number of Number of MUedian survival
Variable Level patients deaths months (%0) P-value
Age in years <25 23 12 29 56 0.0001
25-54 16 9 29 55
55-74 19 19 2 5
)75 14 13 1 14
Gender Male 42 32 7 28 0.29
Female 30 21 11 43
Social class I and 2 12 10 3 33 0.88
3 27 21 6 33
4and5 20 15 10 25
SOC Yes 41 25 22 45 0.0033
No 31 28 3 19
Protocol Yes 55 37 15 43 0.0009
No 14 13 <1 7
Protocol and SOC Yes Yes 27 16 23 46 0.013
Yes No 28 21 14 39
No No 11 10 2 9
SOC. specialist oncology centre.
time of 7 months. The survival curves for place of treatment
are shown in Figure 4. Women appeared to have a survival
advantage with 43% alive at 2 years vs 28% of men.
Fifty-four patients were coded as PSI. PS appeared to
have a significant effect on survival with a median survival of
24 months for the PSI patients vs 2 months for the 18 PS2
and PS3 patients.
There was a strong interaction between age at diagnosis
and whether a patient was treated according to protocol. The
majority of younger patients were treated according to pro-
tocol and fared best and those over 65 years of age and not
so treated fared worst.
As there was little difference in the survival patterns of
leukaemia patients aged under 80 years, age was handled in
the Cox analysis as a two category variable (<80, >80).
Table VIII lists the most significant effect at each step of the
Cox multivariate analysis. PS was the most significant
variable related to survival, followed by grade. Several
interaction effects were incorporated into the model. These
suggested that PS2 and PS3 patients had a better survival if
treated by a recognised protocol, patients aged 80 and over
who were not treated according to a recognised protocol had
a very poor prognosis, and an improved prognosis for
females was most marked for PS3 patients.
Data
A specialist database was set up for the study of
haematological malignancies to make ascertainment more
timely and to ensure diagnostic accuracy. It was also felt that
ascertainment by the NWRCR of low-grade conditions in the
elderly, which may not have required hospital admission,
may have been incomplete.
P-value
0.0001
0.25
0.0001
0.12
0.0001
0.20
0.0001Log-rank P< 0.01
Group 1
- (n= 50)
Group 2
(n= 293)
Group 3
-(n= 148)
0.2
0.1
0.0
0 6 12 18 24 30 36 42 48 54 60
Time (months)
Figwe 3 Survival ofchronic lymphocytic leukaemia by specialist
oncology centre (SOC) and protocol. Group 1, SOC and pro-
tocol; group 2. protocol not SOC; group 3, not SOC and no
protocol.
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Table VlII Final Cox's model for survival for leukaemia patients
M.LE ofregression s.e. of the
Variables P-value coefficient estimate
PS 0.5 x 10 -2 1.0777 0.4043
Grade 0.7 x 10-6 0-9298 0.1885
Protocol and 0.00015 1.0921 0.5480
PS protocol' -0.1244 0.1897
Age and 0.000088 1.6967 0.5562
protocol ages - 0.8407 0.3550
Gender and 0.0029 -0.2766 0.3580
PS gendera -0.0528 0.1704
MLE. maximum likelihood estimate: s.e.. standard error: PS.
performance status. aDenotes first-order interaction effect.
limit the survival analysis of ML to those where pathology
review had been carried out restricted the data set. particular-
ly with regard to patients diagnosed dunrng 1983 and 1984.
All the factors where cases without pathology review differed
from those with review, that is older age, a lower probability
of being treated according to a recognised protocol and a
lower probability of referral to the SOC. would be likely to
bias the results towards a better outcome. Differences in
survival shown by this study are therefore likely to have been
decreased by restricting the data set.
Log-rank P< 0.01
Group 1
(n = 41)
Group 2
(n = 31)
0 6 12 18 24 30 36 42 48 54 60
Time (months)
Fge 4 Survival of acute lymphoblastic leukaemia by specialist
oncology centre (SOC). Group 1, SOC; group 2, not SOC.
Estimates of completeness have been made for the
NWRCR (Benn et al., 1982; Nwene and Smith, 1982) and
for the national cancer registration system (Swerdlow et al.,
1993) and both found ascertainment levels for lymphomas of
about 95%. Cross-validation checks with both the NWRCR
and some laboratories showed that additional cases were
included in the study and accuracy improved. However some
cases of CLL diagnosed on a blood count had not been
notified. The level of ascertainment of cases of ML and ALL,
therefore is high and the study represents one of the few to
attempt to capture a high proportion of cases of CLL.
The diagnosis of all cases was validated and a high propor-
tion of diagnostic material was reviewed. The decision to
Diagnosis
Dick et al. (1987b) reported 'unconventional' or admixed
diagnostic terminology that did not conform to any of the
classification schemes currently in use. This problem led to
errors of coding to ICDO. The same problem contnrbuted to
our decision to exclude cases without review. The findings
from the above study suggested that the unreliability of
subtyping of ML was at least 40% although concurrence
could be as high as 80% for some categonres. In another
series complete concordance of diagnosis was achieved
between submitting pathologists and a lymphoma panel in
just over half the cases (Bird et al., 1984). The results of these
studies are similar to our findings of 47% reclassification and
25% major revision.
In a two level pathology review, good concordance was
found between the regional centre pathologist and the panel
and for the most common lymphomas a second review by
panel was considered unnecessary (Wolf et al., 1988). Kim et
al. (1982) found a discordance of 9% between the regional
centre pathologists and a panel. ML cases in our study were
reviewed by two regional centre pathologists.
Nearly 25% of the changes in diagnosis on review had
clinical relevance. Without such histology review many ML
patients may not receive the most appropriate therapy.
Bartl et al. (1988) found that 12% of trephines were un-
classifiable and a concordance of 76% was found when
lymph node material was available for comparison. Many of
the ML patients in our study diagnosed on bone marrow
examination only had other tissue available for biopsy.
Chemotherapy regimens given to these patients may not have
been the most appropriate.
Staging
The problems surrounding the reconstruction of clinical stage
of disease resulted in a two tier staging system. Analysis of
treatment was carried out on the basis that the information
available in the case notes was the information available to
the clinician when deciding on a treatment plan. However it
is possible that further information was available to the
clinician that was not recorded. No account could be taken
of silent case records in the analysis. The method of defining
stage used in the study did appear to enable stratification by
stage in the analysis in an appropnate manner.
The problem of silent records is a major one for studies of
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health care. Feigl et al. (1988) found that clinical stage was
not routinelv documented but that extent of disease could be
coded in most cases on a crude staging system. Data related
to clinician obsernation. especially performance status was
frequently not available. These findings are similar to the
findings of our study.
Data may be missinz from the hospital records for two
reasons. either the procedure or observation that should have
occurred did not do so. or the result Awas not recorded.
Laboratorx and other diagnostic procedures are generally
reported in the case notes and if the results of a specific test
are not recorded then it is reasonable to assume that the test
was not done. Oxer a quarter of ML cases were insufficiently
investigated to allow full clinical staging before treatment.
w-hich for many of them was intensiv-e therapy. The survival
of cases designated as stage 5 was similar to that of Ann
Arbor stage 2 and 3 patients suggesting that this group
included good prognosis patients w-ho had not been fully
evaluated.
Survival
Published studies give 5 year survival rates for high and
intermediate grade patients of 5000 (Cowan et al.. 1989). An
EORTC trial showed a 3500 5 year survival for high-grade
patients with 5 year survival for low-grade patients of
between 500o and 80°0o. depending on whether the cell pat-
tern was follicular or diffuse (Somers et al.. 1987). The 2-year
survival rate for high-grade patients in our studv was 42%o
and 66%o for low-grade. The median survival for one series
of patients with ALL was 18 months (Barnett et al.. 1986)
and 23 months in another series (Marcus et al.. 1986) com-
pared with a median survival for our study of 7 months for
all ALL patients and 22 months for ALL patients managed
at the SOC.
.4ge
Elderly patients are rarely included in clinical trials and such
patients may be undertreated or inappropriately treated
(Tirelli etal.. 1988: Fentiman etal.. 1990: Fentiman. 1991). A
recent EORTC consensus meeting on neoplasia in the elderly
(Monfardini and Chabner. 1991) concluded that elderlv
patients should receive maximal curative treatment on
accepted protocols and that adjustments to protocols should
not be based on age alone. ML patients presenting over the
age of 65 with high-grade disease and treated with protocols
specifically designed for these patients are reported as achiev-
ing 5 year surnvival rates of 38 -44% (Vose et al.. 1989:
OReillv and Connors. 1992b). These survival rates appear to
exceed the survival of all high grade patients in this study.
however such reports confirm our findings that elderly
patients can do well.
Tirelli et al. (1988) found that 44% of patients in an
EORTC study of patients aged 70 or over were treated
conservatively and 560o were treated aggressively. The cor-
responding proportions for our study were 39% and 25%.
The overall median survival was 37 months. again markedly
in excess of our study. Patients with ALL over the age of 55
were less likely to be referred to the SOC and less likely to be
given chemotherapy at other hospitals. Taylor etal. (1992) in
a population-based study of patients aged 60 and over with
ALL concluded that the prognosis was poor but that age
itself should not be a bar to therapy as a small proportion
can have a good survival. These findings are similar to our
own where a few elderly patients had long-term survival. It
seems likely that many elderly patients are being under-
treated.
Place of treatment
The proportion of patients recorded as entered into ran-
domised climncal tnals was low. Patients were unlikely to have
been entered into a trial unless they had been treated at the
SOC. There did appear to be a possible survival advantage
for clinical trial entry. A higher level of protocol violations
would be probable if trial entnr is not recorded.
The debate about whether clinical trial entry improves
survival has continued for many years and the available data
are still inadequate. Stiller (1992) extensivelv reviewed the
available literature in relation to treatment at specialist cen-
tres or within clinical trials. This review concluded that for
the majority of cancers, the greater clinical experience and
standardisation of treatment. w-hether in the context of
clinical trials or specialist treatment centres or both. is of
direct benefit to patients.
Karjalainen and Palva (1989) found that patients with
multiple myeloma had an improsed survival if thev lived in
an area where clinical trial entry w-as the treatment policy.
The authors concluded that there was a greater level of
uniformity in the trial areas where treatment was according
to a recognised protocol and this was the key factor in an
improv,ed survival. In our study the major benefit to patients
was treatment according to an appropriate standard protocol
but for some ML patients and ALL patients there was an
additional advantage from treatment at a SOC. The impor-
tance of the use of an appropriate protocol was marked for
patients managed at 'other hospitals'. CLL is frequently
perceived as a low-grade disease of the elderly and patients
are rarely managed at a SOC but patients not treated accord-
ing to a protocol fared badly.
Rosenberg (1986). in a review of therapy for Hodgkin's
disease, noted that increasing numbers of patients were being
treated in small community hospitals and felt that this trend
would be detrimental to patient management. Also fewer
patients would be entered into climical trials and therefore it
would be harder to improve survival and decrease therapy-
related morbidity. The improvement of results with ex-
perience provides one of the strongest justifications for
encouraging referral of patients to centres with a specialist
interest in their management (Oliver. 1986). The majority of
hospital groups in this study were responsible for the man-
agement of fewer than five patients a year and verv few such
patients were entered into clinical trials. The survival advan-
tage from management at the SOC for ALL and some ML
patients demonstrates the benefits of experience and speci-
fically that staging is likely to be more precise and treatment
protocols more appropriate for specific patients. Complica-
tions of therapy may also be recognised earlier. In addition
the greater experience may allow the use of less therapy
without compromising survival, reducing the frequencyof the
late effects of treatment. There may also be improved follow-
up and detection of late effects.
Conclusion
Histology review and staging are necessary if patients are to
be appropriately treated. Survival is improved if treatment is
given according to a current standard protocol and may be
further improved bv treatment at a SOC. Specific studies
need to be defined for determining the best treatment for
elderly patients. Although this study has its limitations it is
an additional contribution to the few population-based
studies of adult cancer.
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